PMC:7073332 / 35790-37513
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1060 | 585-594 | Species | denotes | 2019-nCoV | Tax:2697049 |
1061 | 595-605 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
1062 | 1190-1195 | Species | denotes | human | Tax:9606 |
1063 | 1299-1303 | Species | denotes | nCoV | Tax:2697049 |
1064 | 1162-1166 | Species | denotes | HCoV | Tax:694448 |
1065 | 263-273 | Chemical | denotes | Mesalazine | MESH:D019804 |
1066 | 512-522 | Chemical | denotes | mesalazine | MESH:D019804 |
1067 | 1519-1529 | Chemical | denotes | remdesivir | MESH:C000606551 |
1068 | 131-139 | Disease | denotes | toxicity | MESH:D064420 |
1069 | 296-322 | Disease | denotes | inflammatory bowel disease | MESH:D015212 |
1070 | 453-473 | Disease | denotes | pulmonary toxicities | MESH:D008171 |
1071 | 485-494 | Disease | denotes | pneumonia | MESH:D011014 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T174 | 309-314 | Body_part | denotes | bowel | http://purl.org/sig/ont/fma/fma7199 |
T175 | 550-554 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T176 | 564-568 | Body_part | denotes | gene | http://purl.org/sig/ont/fma/fma74402 |
T177 | 611-619 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T178 | 1309-1317 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T179 | 1444-1452 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T10 | 550-554 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T151 | 296-322 | Disease | denotes | inflammatory bowel disease | http://purl.obolibrary.org/obo/MONDO_0005265 |
T152 | 485-494 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T153 | 595-603 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T256 | 9-10 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T257 | 327-328 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T258 | 550-554 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T259 | 550-554 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T260 | 564-568 | http://purl.obolibrary.org/obo/OGG_0000000002 | denotes | gene |
T261 | 1016-1017 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T262 | 1190-1195 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T263 | 1414-1419 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T264 | 1438-1443 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T265 | 1498-1503 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T407 | 32-36 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T408 | 96-101 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T409 | 170-175 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T410 | 180-184 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T411 | 263-273 | Chemical | denotes | Mesalazine | http://purl.obolibrary.org/obo/CHEBI_6775 |
T412 | 287-291 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T413 | 364-368 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T414 | 512-522 | Chemical | denotes | mesalazine | http://purl.obolibrary.org/obo/CHEBI_6775 |
T415 | 611-619 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T416 | 713-718 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T417 | 722-726 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T418 | 896-900 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T419 | 1081-1086 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T420 | 1138-1143 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T421 | 1267-1272 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T422 | 1309-1317 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T423 | 1385-1390 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T424 | 1420-1425 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T425 | 1444-1452 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T426 | 1504-1509 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T427 | 1573-1578 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T428 | 1591-1595 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T25 | 296-322 | Phenotype | denotes | inflammatory bowel disease | http://purl.obolibrary.org/obo/HP_0002037 |
T26 | 485-494 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T221 | 0-249 | Sentence | denotes | Owing to a lack of the complete drug-target information (such as the molecular “promiscuity” of drugs), the dose–response and dose–toxicity effects for both repurposable drugs and drug combinations cannot be identified in the current network models. |
T222 | 250-401 | Sentence | denotes | For example, Mesalazine, an approved drug for inflammatory bowel disease, is a top network-predicted repurposable drug associated with HCoVs (Fig. 5a). |
T223 | 402-534 | Sentence | denotes | Yet, several clinical studies showed the potential pulmonary toxicities (including pneumonia) associated with mesalazine usage81,82. |
T224 | 535-740 | Sentence | denotes | Integration of lung-specific gene expression23 of 2019-nCoV/SARS-CoV-2 host proteins and physiologically based pharmacokinetic modeling83 may reduce side effects of repurposable drugs or drug combinations. |
T225 | 741-846 | Sentence | denotes | Preclinical studies are warranted to evaluate in vivo efficiency and side effects before clinical trials. |
T226 | 847-962 | Sentence | denotes | Furthermore, we only limited to predict pairwise drug combinations based on our previous network-based framework28. |
T227 | 963-1208 | Sentence | denotes | However, we expect that our methodology remain to be a useful network-based tool for prediction of combining multiple drugs toward exploring network relationships of multiple drugs’ targets with the HCoV–host subnetwork in the human interactome. |
T228 | 1209-1323 | Sentence | denotes | Finally, we aimed to systematically identify repurposable drugs by specifically targeting nCoV host proteins only. |
T229 | 1324-1458 | Sentence | denotes | Thus, our current network models cannot predict repurposable drugs from the existing anti-virus drugs that target virus proteins only. |
T230 | 1459-1723 | Sentence | denotes | Thus, combination of the existing anti-virus drugs (such as remdesivir64) with the network-predicted repurposable drugs (Fig. 5) or drug combinations (Fig. 6) may improve coverage of current network-based methodologies by utilizing multi-layer network framework16. |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32194980-23667838-19614242 | 528-530 | 23667838 | denotes | 81 |
32194980-28458997-19614243 | 531-533 | 28458997 | denotes | 82 |
32194980-31375661-19614244 | 579-581 | 31375661 | denotes | 23 |
32194980-29052226-19614245 | 670-672 | 29052226 | denotes | 83 |
32194980-30867426-19614246 | 959-961 | 30867426 | denotes | 28 |
32194980-32020029-19614247 | 1529-1531 | 32020029 | denotes | 64 |